All In Biotech

Drug Trial Radar · NCT03459170

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Feb 1, 2018

Primary completion

Sep 2022

Study completion Sep 2035

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.

Conditions

  • Hematologic Malignancy

Interventions

  • BPX-501 T cellsBiological

    Biological: T cells transduced with CaspaCIDe® safety switch

  • rimiducidDrug

    administered to eliminate BPX-501 cells in the event of GVHD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BPX-501 SafetyTime frame: Month 24
  2. Mean plasma concentrationTime frame: pre-dose, 30 min, 2 hours and 8 hours after start of infusion

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • San Matteo Hospital

    Pavia, Italy

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Rome, Italy

  • Ospedale Infantile Regina Margherita

    Turin, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.